« Previous Next » International Journal of Radiation Oncology * Biology * Physics
Volume 67, Issue 5 , Pages 1323-1331 , 1 April 2007

A Phase II Multi-institutional Trial of Chemoradiation Using Weekly Docetaxel and Erythropoietin for High-Risk Postoperative Head and Neck Cancer Patients

The results of this study were previously presented at the 2004 American Society of Clinical Oncology meeting.

Christopher D. Willey, M.D., Ph.D.
- Department of Radiation Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Barbara A. Murphy, M.D.
- Department of Medical Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
James L. Netterville, M.D.
- Department of Otolaryngology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Brian B. Burkey, M.D.
- Department of Otolaryngology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Yu Shyr, Ph.D.
- Department of Head and Neck Surgery, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Bashar Shakhtour, B.S.
- Department of Head and Neck Surgery, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Bonnie Kish, R.N.
- Department of Biostatistics, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
David Raben, M.D.
- Department of Clinical Trials Office, Vanderbilt University Medical Center, Nashville, Tennessee
Changhu Chen, M.D.
- Department of Radiation Oncology, University of Colorado Health Sciences Center, Denver, Colorado
John I. Song, M.D.
- Department of Otolaryngology, University of Colorado Health Sciences Center, Denver, Colorado
Madeleine A. Kane, M.D., Ph.D.
- Department of Medical Oncology, University of Colorado Health Sciences Center, Denver, Colorado
Anthony J. Cmelak, M.D.
- Department of Radiation Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
- Reprint requests to: Anthony J. Cmelak, M.D., Radiation Oncology, Vanderbilt-Ingram Cancer Center, B-902, The Vanderbilt Clinic, Nashville, TN 37232-5671. Tel: (615) 343-9462; Fax: (615) 343-0161